摘要
目的:探讨利拉鲁肽对超重或肥胖的2型糖尿病(T2DM)患者动脉粥样硬化的影响。方法:选取2017年1月-2018年1月于本院就诊的T2DM合并超重或肥胖的患者60例作为研究对象,按随机数字表法将其分为观察组和对照组,各30例。对照组继续服用原降糖药物治疗,观察组在原降糖药物基础上加用利拉鲁肽治疗。比较两组治疗前后体重、体质量指数(BMI)、空腹血糖(FBG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)、脂联素(APN)、白细胞介素6(IL-6)、超敏C反应蛋白(hs-CRP)及颈动脉内膜中层厚度(CIMT)。分析观察组治疗期间不良反应发生情况。结果:治疗后,观察组体重、BMI及CIMT均低于治疗前与对照组(P<0.05)。治疗后,两组FBG与HbA1c均低于治疗前,且观察组均低于对照组(P<0.05)。治疗后,观察组HOMA-IR、IL-6及hs-CRP均低于治疗前与对照组,而APN高于治疗前与对照组(P<0.05)。观察组中有10例在应用利拉鲁肽后出现轻度恶心,未做处理,3~7 d后症状消失。对治疗效果未产生影响。结论:利拉鲁肽可上调T2DM合并超重或肥胖患者APN水平,在控制血糖的同时降低CIMT,逆转动脉粥样硬化。
Objective:To investigate the effect of Liraglutide on Atherosclerosis(As)in overweight or obese patients with type 2 diabetes mellitus(T2DM).Method:A total of 60 T2DM patients with overweight or obese in our hospital from January 2017 to January 2018 were selected as study subjects.They were divided into observation group and control group according to the random number table method,30 patients in each group.The control group continued to take the original hypoglycemic drugs treatment,the observation group treated with Liraglutide on the basis of the original hypoglycemic drugs.Body weight,body mass index(BMI),fasting blood glucose(FBG),glycosylated hemoglobin(HbA1c),insulin resistance index(HOMA-IR),adiponectin(APN),interleukin 6(IL-6),hypersensitive C-reactive protein(hs-CRP)and CIMT were compared between the two groups before and after treatment.The occurrence of adverse reactions during treatment in the observation group was observed.Result:After treatment,body weight,BMI and CIMT of the observation group were lower than before treatment and those of the control group(P<0.05).After treatment,FBG and HbA1c in both groups were lower than before treatment,and those in the observation group were lower than those in the control group(P<0.05).After treatment,HOMA-IR,IL-6 and hs-CRP in the observation group were lower than before treatment and those in the control group,while APN was higher than that before treatment and those in the control group(P<0.05).In the observation group,10 cases had mild nausea after the application of Liraglutide without treatment,and the symptoms disappeared after 3-7 d.There was no effect on the therapeutic effect.Conclusion:Liraglutide can up regulate APN level in T2DM patients with overweight or obesity,control blood glucose and reduce CIMT.It can reverse atherosclerosis.
作者
解合兰
孙丹丹
王惠丽
XIE Helan;SUN Dandan;WANG Huili(Heze Municipal Hospital,Heze 274031,China;不详)
出处
《中国医学创新》
CAS
2020年第25期13-16,共4页
Medical Innovation of China
